Literature DB >> 3335000

cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

P A Andrews1, S Velury, S C Mann, S B Howell.   

Abstract

We have characterized the accumulation of cisplatin (DDP) into parent and cisplatin-resistant 2008 human ovarian carcinoma cells. Accumulation of DDP at 1 h was a linear function of concentration from 0.25 to 100 microM DDP in both cell types. DDP-resistant cells that were only 3.3-fold resistant had approximately 50% less accumulated platinum at all concentrations examined. Accumulation of 1.0 microM DDP was linear for approximately 3 h and then slowed but did not reach equilibrium at up to 24 h in either cell type. The decreased DDP accumulation in resistant cells did not appear to be due to increased efflux; similar percentages of platinum were available for exodus in parent and resistant cells. Intracellular metabolites of DDP appeared to be decreased by similar amounts in the resistant cells. Native DDP was not driven uphill into cells against a concentration gradient, suggesting that DDP uptake does not involve primary active transport. The metabolic inhibitors, dinitrophenol and NaF, did not decrease DDP accumulation; iodoacetate had a stimulatory effect. Dinitrophenol, however, in combination with NaF or iodoacetate decreased DDP accumulation. A 30-min exposure to 0.2 mM ouabain also decreased DDP accumulation in both parent and resistant cells. A component of DDP accumulation thus appears to be energy dependent. These studies have identified decreased DDP accumulation as an important mechanism of resistance that is expressed early in the acquisition of DDP resistance in human ovarian carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335000

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  68 in total

1.  A mathematical model for cisplatin cellular pharmacodynamics.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

2.  Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.

Authors:  Ding-Wu Shen; Jichun Ma; Mitsunori Okabe; Guofeng Zhang; Di Xia; Michael M Gottesman
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

3.  Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.

Authors:  Amit Kumar Srivastava; Chunhua Han; Ran Zhao; Tiantian Cui; Yuntao Dai; Charlene Mao; Weiqiang Zhao; Xiaoli Zhang; Jianhua Yu; Qi-En Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

4.  DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.

Authors:  Sham S Kakar; Christopher A Worth; Zhenglong Wang; Kelsey Carter; Mariusz Ratajczak; Pranesh Gunjal
Journal:  J Cancer Stem Cell Res       Date:  2016-04-19

5.  In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.

Authors:  Y Heike; M Takahashi; T Ohira; H Arioka; Y Funayama; K Nishio; H Ogasawara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 6.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 7.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence.

Authors:  Wim P Ceelen; Michael F Flessner
Journal:  Nat Rev Clin Oncol       Date:  2009-12-15       Impact factor: 66.675

9.  ATP11B mediates platinum resistance in ovarian cancer.

Authors:  Myrthala Moreno-Smith; J B Halder; Paul S Meltzer; Tamas A Gonda; Lingegowda S Mangala; Rajesha Rupaimoole; Chunhua Lu; Archana S Nagaraja; Kshipra M Gharpure; Yu Kang; Cristian Rodriguez-Aguayo; Pablo E Vivas-Mejia; Behrouz Zand; Rosemarie Schmandt; Hua Wang; Robert R Langley; Nicholas B Jennings; Cristina Ivan; Jeremy E Coffin; Guillermo N Armaiz; Justin Bottsford-Miller; Sang Bae Kim; Margaret S Halleck; Mary J C Hendrix; William Bornman; Menashe Bar-Eli; Ju-Seog Lee; Zahid H Siddik; Gabriel Lopez-Berestein; Anil K Sood
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

10.  Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate.

Authors:  M Markman; B Reichman; T Hakes; R Barakat; J Curtin; S Rubin; W Jones; J L Lewis; L Almadrones; W Hoskins
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.